---
title: "CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278107398.md"
description: "CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S"
datetime: "2026-03-06T13:26:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278107398.md)
  - [en](https://longbridge.com/en/news/278107398.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278107398.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278107398.md) | [繁體中文](https://longbridge.com/zh-HK/news/278107398.md)


# CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S

### Related Stocks

- [CSPC PHARMA (01093.HK)](https://longbridge.com/en/quote/01093.HK.md)
- [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/en/quote/562050.CN.md)

## Related News & Research

- [CSPC Pharmaceutical says indacaterol acetate and mometasone furoate powder for inhalation obtains clinical trial approval in China](https://longbridge.com/en/news/277929926.md)
- [CSPC Pharmaceutical says PDE4B inhibitor obtains U.S. clinical trial approval](https://longbridge.com/en/news/278134678.md)
- [Metal Powder Works to Brief Investors on Half-Year Results via Webinar](https://longbridge.com/en/news/277532294.md)
- [Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion](https://longbridge.com/en/news/277695972.md)
- [Glenmark Pharmaceuticals Gets US FDA Nod for Fluticasone Propionate Inhalation Aerosol](https://longbridge.com/en/news/277723441.md)